Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06607445

Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service.

Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service. Population Cohort [MedeA21].

Status
Recruiting
Phase
Study type
Observational
Enrollment
6,445 (estimated)
Sponsor
Complejo Hospitalario Universitario de Badajoz · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided.

Conditions

Timeline

Start date
2021-05-26
Primary completion
2024-12-31
Completion
2024-12-31
First posted
2024-09-23
Last updated
2024-09-23

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT06607445. Inclusion in this directory is not an endorsement.

Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura He (NCT06607445) · Clinical Trials Directory